News & Updates
Filter by Specialty:

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022
NAFLD tied to CVD risk even in lean patients
Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.
NAFLD tied to CVD risk even in lean patients
06 Jun 2022
Whey protein supplementation aids in blood sugar control in T2D
Drinking a little amount of whey protein before meals helps keep a lid on blood glucose levels of individuals with type 2 diabetes (T2D), as shown in a study.
Whey protein supplementation aids in blood sugar control in T2D
03 Jun 2022
Severe hypoglycaemia linked to tighter glucose control, higher worry scores
Among older Southeast Asian type 2 diabetes mellitus patients, severe hypoglycaemia tends to occur with tighter glycaemic control, greater impaired hypoglycaemia awareness, and higher worry scores, regardless of treatment regimens, according to a study.
Severe hypoglycaemia linked to tighter glucose control, higher worry scores
03 Jun 2022
HRT use tied to reduced COVID-19 death risk
The use of hormonal replacement therapy (HRT) among postmenopausal women may be associated with a reduced risk of mortality after a COVID-19 diagnosis, according to a retrospective study from Sweden.